Search for stocks /

Sharda Cropchem:₹145 Cr PAT. 366% Profit Growth. From Zero to Hero.

Sharda Cropchem Q3 FY26 | EduInvesting
Q3 FY26 Results · Quarterly Results (Oct-Dec)

Sharda Cropchem:
₹145 Cr PAT. 366% Profit
Growth. From Zero to Hero.

Highest-ever quarterly profit. Europe on steroids. Registration moat working overtime. Global farmers are officially hooked on Sharda molecules. And management just keeps calm while the stock is trying to decide if it should care.

Market Cap₹8,920 Cr
CMP₹990
P/E Ratio15.8x
Div Yield0.91%
ROCE16.5%

The Pesticide Exporter That’s Quietly Becoming A Machine

  • 52-Week High / Low₹1,298 / ₹440
  • Q3 FY26 Revenue₹1,289 Cr
  • Q3 FY26 PAT₹145 Cr
  • Quarterly EPS₹16.09
  • Annualised EPS (Q3×4)₹64.36
  • Book Value₹297
  • Price to Book3.34x
  • Dividend Yield0.91%
  • Debt / Equity0.00x
  • TTM Sales (FY25)₹5,031 Cr
The Auditor’s Pre-Flight Check: Sharda Cropchem Q3 FY26 was nothing short of a circus on stilts. Revenue ₹1,289 crore (+39% YoY) pumped by volume growth of 14.4%, forex tailwind of 12.6%, and product-mix magic of 11.6%. PAT ₹145 crore represented a 366% profit jump from ₹31 crore in Q3 FY25. Yes, you read that right. Profit more than quadrupled. The stock? It yawned, shrugged, and continued its 1-year journey of +81% returns. Casual excellence, apparently.

Welcome To The Most Boring Exciting Chemicals Company On NSE

Sharda Cropchem Ltd is the company your farmer uncle buys pesticides from. Well, technically he buys from his local dealer, who bought from a distributor, who sourced from Sharda. It’s a 15-layer supply chain disguised as commerce. And yet — this is the magic — Sharda has zero debt, 3,004 product registrations globally, presence in 80+ countries, and a business model so clean that even accountants weep.

The company was born in 2004 from merging two proprietorships (Sharda International and Bubna Enterprises from 1987-88). It spent the next 20 years doing what most Indian companies say they’ll do but never actually do: quietly building scale. No IPO drama. No “disruption” narrative. No crypto pivot. Just registrations, distributions, and cash. Lots of cash.

Q3 FY26 results arrived with the subtlety of a tractor in a rice paddy. Highest-ever quarterly PAT of ₹145 crore. 9M FY26 PAT already ₹362 crore — triple the prior year. Revenue growth at 29% for nine months. Europe contributing 60% of agrochemical revenues. Management casually mentioned on the concall that this business is “asset-light,” which is CEO-speak for “we own almost nothing but somehow make stacks of money.”

Let’s break down what happens when a pesticide exporter decides to execute flawlessly for eight quarters straight.

Concall Gold (Jan 2026): Management stated: “We are looking into increasing the dividend, but we are not looking into acquisitions.” Translation: 826 crore in cash. Zero M&A fever. Pure return-to-shareholder mode. Even private equity firms would nod in approval.

Copy Molecules. Register Them. Sell Globally. Repeat.

Here’s the business distilled to its essence: Sharda doesn’t invent new pesticides. They watch big pharma and agrochemical majors. When blockbuster molecules go off-patent, Sharda swoops in, creates dossiers (regulatory compliance paperwork), files registrations in target geographies (Europe, NAFTA, LATAM, Rest of World), and launches formulations under their own label. All manufacturing is outsourced — primarily to China. Distribution? 525+ third-party distributors and 500+ sales personnel operating in 80+ countries. Asset-light. Margin-fat.

The registrations are the moat. Why? Because regulators don’t allow “freely tradable” agrochemical products. Every country has its own approval process. Once Sharda registers a molecule in, say, France, that registration is Sharda’s intellectual property in that jurisdiction. Competitors can’t just buy the same chemical off Alibaba and sell it. They need their own registrations. Sharda has 3,004. That’s the fortress.

Segment mix: Agrochemicals (87% of sales) includes herbicides (52% of agro sales), insecticides (26%), and fungicides (23%). Non-agrochemicals (13% of sales) cover dyes, conveyor belts, and rubber goods — basically financial rounding errors masquerading as business segments. Geography matters more: Europe accounts for 60% of agro revenues, NAFTA 28%, LATAM 7%, Rest of World 5%. Europe is the profit engine. NAFTA is high-volume, low-margin grunt work.

Herbicides52%of Agro Sales
Insecticides26%of Agro Sales
Fungicides23%of Agro Sales
Total Registrations3,004as of Dec 31
The Registration Trap: Sharda invests ₹450-500 crore annually in product registrations. These aren’t R&D labs. They’re regulatory dossier teams, clinical trial outsourcers, and compliance engineers. Capex for registrations = fixed cost. But conversions (applications approved) = probabilistic upside. Management admitted timelines are “full of uncertainties” — “1 year or 2 years… [or] 6 to 7 years.” Classic biotech drug metaphor, except for weedkillers.
💬 If Sharda owns 3,004 registrations globally, why does the stock trade at only 3.34x book value while Bayer Crop trades at 30x P/E? Is the market sleeping, or is registration quality the real game?

Q3 FY26: The Numbers Are Genuinely Feral

Continue reading with a premium membership.
Become a member
error: Content is protected !!